Neuralstem, Inc. to Present At World Stem Cells and Regenerative Medicine Congress
ROCKVILLE, Md., May 10 /PRNewswire-FirstCall/ -- Neuralstem,
Inc. (NYSE Amex: CUR) CEO and President, Richard Garr, has been
invited to present at the Fifth Annual World Stem Cells and
Regenerative Medicine Congress, held May 11-13, in London, UK
http://www.terrapinn.com/2010/stemcells/index.stm.
Neuralstem is currently in a Phase I clinical trial to treat ALS
(Amyotrophic Lateral Sclerosis, or Lou Gehrig's disease) with its
spinal cord stem cells.
(Logo: http://www.newscom.com/cgi-bin/prnh/20061221/DCTH007LOGO
)
Mr. Garr's talk, at 2:30 on Wednesday, May 12, is entitled
"Goals, Challenges and Solutions for Bringing Cell-Based ALS
Therapy to the Clinic." It will address the goals and scientific
potential of applying cell therapy to ALS, as well as the
challenges and solutions in bringing this treatment to
patients.
About Neuralstem, Inc.
Neuralstem's patented technology enables, for the first time,
the ability to produce neural stem cells of the human brain and
spinal cord in commercial quantities, and the ability to control
the differentiation of these cells into mature, physiologically
relevant human neurons and glia. The company is targeting major
central nervous system diseases including: Ischemic Spastic
Paraplegia, Traumatic Spinal Cord Injury, Huntington's disease and
Amyotrophic Lateral Sclerosis (ALS), often referred to as Lou
Gehrig's disease. ALS is a progressive fatal neurodegenerative
disease that affects nerve cells in the brain, leading to the
degeneration and death of the motor neurons in the spinal cord that
control muscle movement. Neuralstem is in a Phase I clinical trial
to treat ALS. For more information, please go to
www.neuralstem.com.
Cautionary Statement Regarding Forward Looking Information
This news release may contain forward-looking statements made
pursuant to the "safe harbor" provisions of the Private Securities
Litigation Reform Act of 1995. Investors are cautioned that such
forward-looking statements in this press release regarding
potential applications of Neuralstem's technologies constitute
forward-looking statements that involve risks and uncertainties,
including, without limitation, risks inherent in the development
and commercialization of potential products, uncertainty of
clinical trial results or regulatory approvals or clearances, need
for future capital, dependence upon collaborators and maintenance
of our intellectual property rights. Actual results may differ
materially from the results anticipated in these forward- looking
statements. Additional information on potential factors that could
affect our results and other risks and uncertainties are detailed
from time to time in Neuralstem's periodic reports, including the
annual report on Form 10-K for the year ended December 31,
2009.
Photo: http://www.newscom.com/cgi-bin/prnh/20061221/DCTH007LOGO
AP Archive: http://photoarchive.ap.org/
PRN Photo Desk, photodesk@prnewswire.com
Source: Neuralstem, Inc.
CONTACT: Richard Garr, President, +1-301-366-4960, or Meg
McElroy,
Shareholder Relations, +1-301-366-4960, or Deanne Eagle,
Planet
Communications, Media, +1-917-837-5866
Web Site: http://www.neuralstem.com/
Posted: May 2010
